AGC Biologics A/S: Financial statements 2018
CVR: 25950941
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
AGC Biologics A/S (CVR 25950941) has filed annual accounts for 2018. In 2018, the company reported revenue of DKK 692,613,000 and a net result of DKK 96,167,000 compared with DKK 74,528,000 the year before. That is an increase of 7.6% compared with the year before. The profit margin was 13.9%. Equity in the 2018 report amounted to DKK 316,811,000. The solvency ratio was 49.9%. The company had 312 employees in the financial year.
- Revenue
- DKK 692,613,000
- Gross Profit
- DKK 162,263,000
- Profit/Loss
- DKK 96,167,000
- Equity
- DKK 316,811,000
- Total Assets
- DKK 634,585,000
- Employees
- 312
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | 692.6M | 162.3M | 96.2M | 316.8M | 312 |
| 2017 | 643.6M | 156.8M | 74.5M | 290.6M | 303 |
| 2016 | 521.8M | 116.1M | 68.2M | 216.1M | 245 |
| 2015 | 320.5M | 62.3M | 8.4M | 147.9M | 209 |
| 2014 | 311.1M | 45.8M | 3.2M | 139.5M | 199 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
On November 30, 2018, the company changed its name from CMC BIOLOGICS A/S to AGC Biologics A/S.
As of October 3, 2018, Hideyuki Kurata has joined the board of directors of AGC Biologics A/S.
As of October 3, 2018, Noriyuki Komuro has joined the board of directors of AGC Biologics A/S.
As of October 2, 2018, Hideyuki Kurata has left the board of directors of AGC Biologics A/S.
As of October 2, 2018, Noriyuki Komuro has left the board of directors of AGC Biologics A/S.
As of September 17, 2018, Noriyuki Komuro has joined the board of directors of AGC Biologics A/S.
As of August 31, 2018, Yukiteru Nakashita has left the board of directors of AGC Biologics A/S.
AGC Biologics A/S has published its annual report for 2017. Revenue came to DKK 643,563,000, and the net result was DKK 74,528,000.
As of January 31, 2018, Hiroshi Nishimura has joined the board of directors of AGC Biologics A/S.
As of January 31, 2018, Masahiko Fukamachi has left the board of directors of AGC Biologics A/S.
About AGC Biologics A/S
AGC Biologics A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 2001. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named CMC BIOLOGICS A/S and CMC BIOPHARMACEUTICALS A/S. The management consists of Kasper Møller. The board consists of Tadashi Murano (chair), Alberto Santagostino, Kasper Møller and Mai Iwaya. The company is owned by Asahi Glass Co., Ltd.. The company has 1,503 employees (2026). In 2025, the company reported revenue of DKK 1,959,639,000 and a net result of DKK -328,010,000 compared with DKK -115,005,000 the year before. Equity in the 2025 report amounted to DKK 312,021,000.
